Grifols reported EUR1.6B in Operating Expenses for its fiscal quarter ending in December of 2024.


Operating Expenses Change Date
Alaunos Therapeutics USD 759K 391K Dec/2024
GlaxoSmithKline GBP 5.96B 663M Jun/2025
Grifols EUR 1.6B 128.03M Dec/2024
Life Technologies USD 20.31M 4.49M Jun/2025